Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
According to the terms of the agreement, Madrigal will pay Arrowhead a $25 million upfront payment, with the possibility of up to an additional $975 million in future payments based on research and development milestones. This collaboration involves Arrowhead's proprietary technology in the treatment of non-alcoholic steatohepatitis (NASH). Both parties will jointly advance the development of related therapies, and Arrowhead is expected to receive total revenue of up to $1 billion through the achievement of specific development, registration, and commercial milestones. This collaboration highlights the recognition of Arrowhead's technological strength in the field of RNA interference therapies within the industry.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Vitalik's Associated Address Transfers 7,000 ETH, Possibly Heading to a Centralized Exchange
BlockBeats•2026/06/27 07:13
Trending news
MoreCrypto prices
MoreBitcoin
BTC
$60,294.97
-0.24%
Ethereum
ETH
$1,579.22
+0.17%
Tether USDt
USDT
$0.9985
-0.00%
USDC
USDC
$0.9997
+0.00%
XRP
XRP
$1.06
+1.21%
Solana
SOL
$72
+2.23%
TRON
TRX
$0.3204
-0.61%
Hyperliquid
HYPE
$63.55
-0.21%
Dogecoin
DOGE
$0.07562
+0.96%
Zcash
ZEC
$408.26
-1.38%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now